A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 796-809

  Ali, Mirza Zaki ^b   Goetz, Matthew Bidwell ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTRIAXONE; CEFUROXIME; GENTAMICIN; NETILMICIN; SISOMICIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY TRACT INFECTION; VESTIBULAR DISORDER;

EID: 0030893852     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.796     Document Type: Article

References (23)

1. Fantin B, Ebert S, Leggett J, Vogelman D, Craig WA. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. J Antimicrob Chemother 1990;27:829-36.
2. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993;31(suppl D):149-58.
3. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single, large daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988;158:7-12.
4. Blaser J, Stone BB, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother 1985;27:343-9.
5. Gerber AU, Kozak S, Segessenmann C, Flückiger U, Bangerter T, Greter U. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis 1989;8:233-7.
6. Craig WA, Vogelman B. The postantibiotic effect [editorial]. Ann Intern Med 1987;106:900-2.
7. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157:287-98.
8. Isaksson B, Nilsson L, Maller R, Sörén L. Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method. J Antimicrob Chemother 1988;22:23-33.
9. Kapusnik JE, Sande MA. Challenging conventional aminoglycoside dosing regimens: the value of experimental models. Am J Med 1986;80(suppl 6B):179-81.
10. Gerber AU, Brugger H-P, Feller C, Stritzko T, Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis 1986;153:90-7.
11. Giuliano RA, Verpooten GA, De Broe ME. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis 1986;8:297-303.
12. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat: comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986;77:1492-500.
13. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22-7.
14. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991;27(suppl C):41-7.
15. Frame PT, Phair JP, Watanakunakorn C, Bannister TWP. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977;135:952-6.
16. Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978;4(suppl A):85-101.
17. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979;140:576-80.
18. Wood CA, Norton DR, Kohlhepp SJ, et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988;158:13-22.
19. Tran Ba Huy P, Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol (Stockh) 1988;105:511-5.
20. Pettorossi VE, Ferraresi A, Errico P, Draicchio F, Dionisotti S. The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. Eur Arch Otorhinolaryngol 1990;247:277-82.
21. Takumida M, Nishida I, Nikaido M, Hirakawa K, Harada Y, Bagger-Sjöbäck D. Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. ORL J Otorhinolaryngol Relat Spec 1990;52:341-9.
22. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100:352-7.
23. Smith CR, Baughman KL, Edwards CQ, Rogers JF, Lietman PS. Controlled comparison of amikacin and gentamicin. N Engl J Med 1977;296:349-53.